SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. NASDAQ:SLS (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical data from studies…